Metabolic studies in patients with nadolol: oral and intravenous administration.
about
Effect of nadolol in treatment of hypertensionEvaluation of in vivo partial beta 1/beta 2-agonist activity: a dose-ranging study with carteolol.Comparative pharmacological and pharmacokinetic observations on propranolol (long acting formulation) and bendrofluazide administered separately and concurrently to volunteersImproved physical performance as a therapeutic objective in patients with angina.Long-term treatment of essential hypertension using nadolol and hydrochlorothiazide combined.Elimination of nadolol by patients with renal impairment.A comparison of the effects of intravenous propranolol and nadolol on the renal response to hypertonic saline infusion.Ontogeny of drug elimination by the human kidney.Absorption of the beta-adrenergic-blocking agent, nadolol, by mice, rats, hamsters, rabbits, dogs, monkeys, and man: an unusual species difference.Angina pectoris: effective therapy once daily.Pharmacokinetics of nadolol, a beta-receptor antagonist: administration of therapeutic single- and multiple-dosage regimens to hypertensive patients.Modulation of tight junctions does not predict oral absorption of hydrophilic compounds: use of Caco-2 and Calu-3 cells.Selectivity of antagonist and partial agonist activity of celiprolol in normal subjects.Cardiovascular effects of single oral doses of the new beta-adrenoceptor blocking agents betaxolol (SL 75212) in healthy volunteers.Comparison of the duration of effect of metoprolol and a sustained release formulation of metoprolol (betaloc-SA).Pharmacokinetics of nadolol in children with supraventricular tachycardia.Nadolol for Treatment of Supraventricular Tachycardia in Infants and Young Children.
P2860
Q28317286-2B37B7C3-B6A8-4271-8A7B-3A1C99AEA520Q34402972-ACE3A0FE-090F-4C34-9293-FCE3D30E5045Q34511212-B76E82F8-856B-4DD8-8519-AB3AC4D595D0Q34516462-768784A2-7B5A-4E98-B368-BF3F0C301791Q34516475-9E38C779-984C-4661-94C6-F90FB161A353Q34516483-D05AD1D4-4404-4A3F-90F2-45F62FE559C5Q34622494-907C5814-D98B-41AE-8861-F12EE39CDF8FQ36332516-6B06B643-E01E-44B4-9FB0-0713EC59EA6CQ39210510-9ADB8A3A-46FC-49C4-A680-6680C6E8AB75Q39238448-B5FF9333-38A7-42DB-9B74-4103A5090390Q39300419-254AFE83-C5AF-4843-AD24-BE386C1A3B7EQ40078702-C4EA9855-1834-468A-B786-D3CFE4727D28Q42049555-1811D63A-6058-49EB-B406-218B52DA8563Q42265870-C448DBC2-FBD8-499D-9B85-76511599D89DQ43240935-FC78B435-4D56-40B3-B5DB-4E4370C051FCQ44297638-85F9FA38-91CD-4085-A85E-C385ED1E0216Q52773905-8BC6A942-7ACF-45AE-BE06-E51047334DDD
P2860
Metabolic studies in patients with nadolol: oral and intravenous administration.
description
1977 nî lūn-bûn
@nan
1977年の論文
@ja
1977年論文
@yue
1977年論文
@zh-hant
1977年論文
@zh-hk
1977年論文
@zh-mo
1977年論文
@zh-tw
1977年论文
@wuu
1977年论文
@zh
1977年论文
@zh-cn
name
Metabolic studies in patients with nadolol: oral and intravenous administration.
@en
Metabolic studies in patients with nadolol: oral and intravenous administration.
@nl
type
label
Metabolic studies in patients with nadolol: oral and intravenous administration.
@en
Metabolic studies in patients with nadolol: oral and intravenous administration.
@nl
prefLabel
Metabolic studies in patients with nadolol: oral and intravenous administration.
@en
Metabolic studies in patients with nadolol: oral and intravenous administration.
@nl
P2093
P1476
Metabolic studies in patients with nadolol: oral and intravenous administration.
@en
P2093
Brannick LJ
Dreyfuss J
Vukovich RA
Willard DA
P2860
P304
P356
10.1002/J.1552-4604.1977.TB04609.X
P577
1977-05-01T00:00:00Z